Physician profile
Mitchell Cagle
NPI 1306396676
$13,372.12
in general payments reported to CMS, 2019-2025
42 companies · $1,860 in 2025
The $1,860 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,396 · 2022: $3,029 · 2023: $2,981 · 2024: $2,106 · 2025: $1,860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,847 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,847.33 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,722.14 | 2021-2025 | |
| Novo Nordisk INC | $1,201.51 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $981.95 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $911.39 | 2021-2025 | |
| Lilly USA, LLC | $900.23 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $877.45 | 2021-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $720.52 | 2021-2025 | Jardiance, Ofev |
| Daiichi Sankyo INC. | $712.94 | 2021-2023 | Injectafer |
| Novartis Pharmaceuticals Corporation | $583.91 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $503.22 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $495.49 | 2021-2024 | Xarelto |
| Esperion Therapeutics, INC. | $456.70 | 2021-2025 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $345.15 | 2021-2025 | Trintellix |
| Amgen INC. | $329.68 | 2021-2025 | Repatha, Otezla, Evenity |
| Abbott Laboratories | $323.95 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Cagle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.